(Total Views: 495)
Posted On: 08/01/2023 10:09:59 AM
Post# of 154032
ohm wrote:
<<With no approvals and no competitor to measure against there's a higher likelihood of approval. When it comes to profit, no competitors and a large patient population gives NASH the win.>>
What do you think about the competitive potential of Ocaliva described as the "farnesoid X receptor (FXR) agonist obeticholic acid (Ocaliva, Intercept Pharmaceuticals). This drug acts on a nuclear receptor that has very broad effects on lipid metabolism, inflammation, and, subsequently, fibrosis."
<<With no approvals and no competitor to measure against there's a higher likelihood of approval. When it comes to profit, no competitors and a large patient population gives NASH the win.>>
What do you think about the competitive potential of Ocaliva described as the "farnesoid X receptor (FXR) agonist obeticholic acid (Ocaliva, Intercept Pharmaceuticals). This drug acts on a nuclear receptor that has very broad effects on lipid metabolism, inflammation, and, subsequently, fibrosis."
(2)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
